Press release from Companies
Publicerat: 2025-07-10 11:57:03
SensoDetect Sweden is proud to announce major advancements in its China operations following a successful strategic mission to the country from June 26 to July 3. The visit brought together key representatives from both SensoDetect Sweden and its joint venture partner, Beijing Mind Exploration Medical Technology Co., Ltd. (BME), solidifying critical alliances and launching new initiatives aimed at transforming neuropsychiatric diagnostics across China.
Led by Johan Möllerström (Chairman), Wendi Ma (Board Member), and PA Hedin (CEO), SensoDetect’s delegation collaborated with BME leadership—Dr. Liu Hai (President) and Zheng Shaoqi (Deputy GM)—engaging with top-tier decision-makers and investors in Beijing, Nantong, and Nanjing.
"We’re not just building devices — we’re building the future of mental health diagnostics in one of the world’s most dynamic healthcare markets," said PA Hedin, CEO of SensoDetect.
"This visit was a breakthrough — deepening high-level partnerships, setting up a production site for our new hardware, and laying the foundation for massive scale."
The week included pivotal meetings with influential stakeholders, including:
"There’s a shared understanding that early diagnosis is the key to changing outcomes," said Dr. Liu Hai, President of BME. "With this joint venture and our new strategic partners, we’re delivering world-class diagnostic innovation to the entire Chinese healthcare system."
In a significant product update, BME will enhance its application to the Chinese NMPA with a redesigned device, BME 1.1, targeting regulatory approval in 2025. This mobile version will be followed by BME 2.0, a stationary unit equipped with Evoked Response Potential (ERP) technology for deeper diagnostics. BME 2.0 is targeting approval in 2026 (see pdf BME 1.1 and 2.0 PR 20250710 for more information).
The joint venture is launching a clinical study involving over 600 ADHD patients across major hospitals in Beijing, Nantong, and Nanjing. Additionally, pilot programs in schools are being rolled out—generating pre-approval revenue while increasing brand exposure and clinical validation.
"The demand for accurate, objective diagnostics for children with ADHD and ASD is overwhelming," said Wendi Ma, Board Member of SensoDetect. "China is ready, and we are bringing the tools."
SensoDetect and BME are in advanced discussions with the regional government of Nantong to establish a new production hub for both BME 1.0 and BME 2.0. Negotiated benefits include:
With a population of 8 million and proximity to the economic powerhouse of Shanghai, Nantong offers a strategic and scalable manufacturing base.
BME is forming a strategic partnership with SinoPharm (China National Pharmaceutical Group Co., Ltd.), the country’s largest pharmaceutical and healthcare group, and one of the largest medical distributors globally. Highlights include:
"Partnering with SinoPharm gives us instant access to hospitals, clinics, and care centers throughout China — and beyond," said Zheng Shaoqi, Deputy GM of BME.
China presents one of the world’s largest untapped markets for neurodevelopmental diagnostics:
Revenue Potential
BME 1.1 (mobile):
BME 2.0 (stationary, ERP-enabled):
"This is more than expansion — it’s transformation," said Chairman Johan Möllerström.
"SensoDetect’s vision is becoming reality: scalable, highly profitable, scientifically validated diagnostics in the hands of those who need it most — starting with millions of children across China."
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
pa.hedin@sensodetect.com
SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of diagnostics, medication, and health. The products are used in both private and public healthcare as a complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.
More info at https://www.sensodetect.com/
